Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report by Koziński, Marek et al.
ORIGINAL ARTICLE
Cardiology Journal
2008, Vol. 15, No. 6, pp. 530–536
Copyright © 2008 Via Medica
ISSN 1897–5593
530 www.cardiologyjournal.org
Address for correspondence: Marek Koziński, MD, PhD, Department of Cardiology and Internal Medicine,
Skłodowskiej-Curie 9, 85–094 Bydgoszcz, Poland, tel: +48 52 585 40 23; fax: +48 52 585 40 24;
e-mail: marekkozinski@wp.pl
Received: 14.07.2008 Accepted: 1.09.2008
Increased morning ADP-dependent
platelet aggregation persists despite
dual antiplatelet therapy in patients with first
ST-segment elevation myocardial infarction:
Preliminary report
Marek Koziński1, Liliana Bielis2, Joanna Wiśniewska-Szmyt1,
Adam Sukiennik1, Zofia Grąbczewska1, Iwona Świątkiewicz1,
Michał Ziołkowski2, Danuta Rość2, Jacek Kubica1
1Department of Cardiology and Internal Medicine, Collegium Medicum,
Nicolaus Copernicus University, Bydgoszcz, Poland
2Department of Pathophysiology, Collegium Medicum,
Nicolaus Copernicus University, Bydgoszcz, Poland
Abstract
Background: Numerous trials have reported on the morning increase in the occurrence of
myocardial infarction, stroke and sudden cardiac death. Similarly, enhanced morning platelet
aggregation has been observed in healthy individuals and in subjects with coronary artery disease
without adequate antiplatelet treatment. The purpose of the study was to assess circadian variation
in platelet aggregation in patients with first ST-elevation myocardial infarction (STEMI) treated
with primary percutaneous coronary interventions (pPCI) and dual antiplatelet therapy.
Methods: Fifteen consecutive patients (12 men and 3 women) were prospectively recruited into
the study. Blood samples were collected at 6.00 a.m., 10.00 a.m., 2.00 p.m. and 7.00 p.m. on the
third day of hospitalization. Aggregation in response to arachidonic acid and adenosine diphos-
phate (ADP) was assessed in the whole blood on a new generation impedance aggregometer.
Results: A morning increase of 75% in ADP-dependent platelet aggregation was noted in the
study population (p < 0.04). In contrast, we failed to show any significant diurnal variation in
arachidonic acid-mediated platelet aggregation. The magnitude of the morning surge in plate-
let aggregation after ADP stimulation did not correlate with its baseline level.
Conclusions: Increased morning ADP-dependent platelet aggregation persists despite dual
antiplatelet therapy in patients with first STEMI undergoing pPCI. The clinical significance of
this finding remains to be demonstrated. (Cardiol J 2008; 15: 530–536)
Key words: platelet aggregation, circadian variation, antiplatelet therapy, acute
myocardial infarction
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Introduction
Platelets play a pivotal role in the pathogene-
sis of acute coronary syndromes. Based on the im-
pressive results of landmark trials, antiplatelet
agents constitute the cornerstone of therapy in the
acute phase as well as in secondary prevention in
this setting [1, 2]. However, despite the widespre-
ad utilization of antiplatelet therapy, adverse car-
diac events continue to occur in a substantial pro-
portion of patients. In recent years significant in-
ter-individual variability in response to antiplatelet
drugs has been observed [3, 4]. Insufficient plate-
let inhibition was proposed to account for many of
the ischemic complications. Furthermore, numero-
us reports linking both aspirin- and clopidogrel-
-resistance with unfavourable clinical outcomes
supported this hypothesis [5–8]. On the other hand,
hyperresponsiveness to aspirin and thienopyridines
may pose a serious threat of bleeding. Due to the
limited number of patients and events in these stu-
dies, it remains unclear whether platelet function
testing should be routinely performed. In addition,
optimal methods of measurement of platelet aggre-
gation and cut-off values associated with high car-
diovascular risk are yet to be determined. The re-
levance of these issues is growing, with the broad
adoption of drug-eluting stents altering the vessel
wall healing process that results in the necessity
for prolonged dual antiplatelet therapy.
Most of the studies suggesting a close relation
between enhanced platelet aggregation and unfavo-
urable clinical outcome do not specify the exact ti-
ming of blood sampling [6–8]. This fact seems to be
of a great importance, taking into account previous
observations regarding increased morning platelet
aggregation in healthy and hypertensive subjects, as
well as in patients with coronary artery disease wi-
thout adequate antiplatelet treatment, along with the
phenomenon of morning excess of myocardial infarc-
tion, stroke and sudden cardiac death [9–15].
The purpose of the study was to assess circa-
dian variation in platelet aggregation in patients
with first ST-segment elevation myocardial infarc-
tion (STEMI) treated with primary percutaneous
coronary interventions (pPCI) and dual antiplate-
let therapy.
Methods
Study design and patients
Fifteen consecutive patients (12 men and
3 women) admitted to the Department of Cardiology
and Internal Medicine of the Collegium Medicum
in Bydgoszcz with a diagnosis of first STEMI and
designated to undergo pPCI were prospectively
recruited into the study. The enrolment criteria
included: typical anginal pain at rest for at least
20 min, symptom onset less than 12 h before the
admission to hospital and electrocardiographic fe-
atures of currently evolving STEMI (elevation of
ST segment ≥ 0.1 mV in at least two limb leads or
≥ 0.2 mV in at least two precordial leads). Trial
exclusion criteria consisted of:
— age under 18 years or over 80 years;
— history of previous myocardial infarction;
— prior coronary revascularisation;
— cardiogenic shock at admission or initiation of
the treatment with vasopressors before pPCI;
— bundle branch block;
— history of chronic heart failure in functional
class III or IV of the New York Heart Associa-
tion (NYHA), or hemodynamically significant
valvular heart disease or idiopathic cardiomyo-
pathy;
— history of cardiac pacing or indications for tem-
poral cardiac pacing;
— persistent atrial fibrillation or other indication
for oral anticoagulants;
— thrombocytopenia (< 100 000/mm3) or history
of congenital or acquired bleeding disorder;
— history of malignant neoplasm in the previous
5 years;
— recent trauma or major surgery (within the
2 months prior to enrolment);
— chronic obstructive pulmonary disease;
— any symptomatic concomitant infection;
— any concomitant immunosuppressive therapy
including the use of steroids;
— chronic kidney disease defined as serum cre-
atinine > 2 mg/dL or the need for renal repla-
cement therapy.
All participants provided informed written con-
sent. The clinical characteristics of the patient po-
pulation are presented in Table 1. The study proto-
col was approved by the Local Ethics Committee.
Pharmacotherapy
At first contact with health care providers im-
mediately after diagnosis of STEMI all patients
were pretreated with an intravenous bolus of
unfractionated heparin (70 IU/kg, but not more
than 5000 IU) and oral loading doses of clopidogrel
(600 mg) and aspirin (300 mg). At the catheterization
laboratory a second dose of unfractionated heparin was
intra-arterially administered in a weight-adjusted
manner (up to 100 IU/kg) or under activated clot-
ting time guidance (to the target range 200–250 s) if
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abciximab, a blocker of platelet glycoprotein IIb/IIIa,
was intended. Abciximab was given at the discre-
tion of the invasive cardiologist. Throughout the
hospitalization period clopidogrel and acetylsalicy-
lic acid were continued in single doses of 75 mg
given at 8.00 a.m. Post-discharge antiplatelet the-
rapy was planned in accordance with current Euro-
pean recommendations. Concomitant medications
in all patients included ramipril and bisoprolol pro-
vided at 8.00 a.m. in doses adjusted for resting he-
art rate and blood pressure, as well as atorvastatin
administered at 8.00 p.m.
Percutaneous coronary interventions
Coronary angiography and pPCI procedures
were performed using the standard technique via
the femoral artery with the aid of an Integris Allura
device (Philips, the Netherlands). Non-ionic low-
osmolar contrast media were applied. During angio-
graphy at least 5 left coronary artery and 3 right
coronary artery projections were taken after a pre-
vious administration of 0.3 mg nitroglycerine into
the coronary vessels, if arterial pressure was suffi-
cient. Epicardial coronary flow was assessed accor-
ding to the Thrombolysis in Myocardial Infarction
(TIMI) scale. In all patients bare metal stents were
implanted. The optimal direct effect of the interven-
tion was assigned when no residual stenosis or
a stenosis of less than 20% of the reference seg-
ment diameter was observed. Detailed characteri-
stics of the procedures are displayed in Table 2.
Measurement of platelet aggregation
Blood samples were collected into hirudin-con-
taining tubes at 6.00 a.m., 10.00 a.m., 2.00 p.m. and
7.00 p.m. The third day of hospitalization was cho-
sen for blood sampling because at this time the pa-
tient with acute myocardial infarction is usually mo-
bile, leaves the coronary care unit, and both aspirin
and clopidogrel fully exert their antiplatelet proper-
ties. If a patient was admitted after 7.00 p.m., the next
day was counted as the first day of hospital stay.
Platelet counts evaluated on the third day of
hospitalization ranged from 125 × 103/mL to 317 ×
× 103/mL, with a median value of 220 × 103/mL,
Table 1. Clinical characteristics of the study
population (n = 15).
Age [years] 56.0 (50.0–65.0)
Gender [male/female] 12/3
Infarct location: 6/8/1
anterior/inferior/lateral wall
Time from symptom onset [h] 3.5 (2.5–8.0)
CKmax [U/L] 1589.0 (258.0–2506.0)
CK-MBmax [U/L] 254.0 (50.0–361.0)
TnImax [ng/ml] 36.7 (4.5–50.0)
LVEF [%] 47.5 (42.5–50.0)
Risk factors of CAD
Body mass index [kg/m2] 25.7 (24.9–31.9)
Arterial hypertension 6
Diabetes mellitus 5 including 3 newly
diagnosed patients
Current smokers 9
History of smoking 4
Positive family history 4
Total cholesterol [mg/dl] 249.5 (201.0–268.0)
LDL cholesterol [mg/dl] 170.5 (121.0–203.0)
HDL cholesterol [mg/dl] 49.5 (39.0–58.0)
Triglycerides [mg/dl] 90.0 (61.0–120.0)
LVEF — left ventricular ejection fraction, CAD — coronary artery disease
Table 2. Angiographic and procedural characte-
ristics of the study population (n = 15).
Coronary artery disease:
Single-vessel 8
Multivessel 7
Localization of culprit lesion:
Left anterior descending artery 4
Diagonal branch 1
Intermediate artery 1
Circumflex artery 1
Obtuse marginal artery 2
Right coronary artery 6
Baseline blood flow in the culprit vessel:
TIMI 0 7
TIMI 1 2
TIMI 2 0
TIMI 3 6
Final blood flow in the culprit vessel:
TIMI 3 15
Usage of abciximab 3
Direct stenting 12
Multivessel primary PCI 0
Number of implanted stents:
1 13
2 2
Total length of 18.0 (17.0–22.0)
implanted stents [mm]
Maximal stent or 3.5 (2.7–4.0)
balloon diameter [mm]
Maximal inflation pressure [atm] 17.0 (16.0–20.0)
Outcome of primary PCI:
Effective 15
Ineffective 0
Revascularization:
Complete 10
Incomplete 5
Qualification for further treatment:
Conservative 13
PCI 1
CABG 1
PCI — percutaneous coronary interventions; CABG — coronary artery
bypass grafting
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whereas mean platelet volume was 10.8 fL (range
10.2–13.3 fL). Aggregation in the whole blood was
assessed within 2 h of the venipuncture on a new
generation impedance analyzer with multiple elec-
trode aggregometry according to the manufactu-
rer’s instructions [16]. This method is capable of
detecting the effect of both clopidogrel and aspirin
treatment, and its results prior to, and after, anti-
platelet treatment correlate well with light trans-
mission aggregometry [17]. The whole procedure
of platelet aggregation measurement with a Multi-
plate® (Dynabyte, Munich, Germany) device was
performed in approximately 10 min. Whole blood,
which was utilized in our study, is the physiologi-
cal environment in which platelet function takes
place in vivo. Moreover, the use of whole blood for
in-vitro testing eliminates the need for the time-
consuming centrifugation steps required to obtain
platelet-rich plasma necessary for light transmis-
sion aggregometry. Therefore, it must be stressed
that impedance aggregometry and light transmis-
sion aggregometry measure different aspects of
platelet function. Impedance aggregometry results
reflect interactions between platelets, red and white
cells, while light transmission aggregometry does
not [18]. Dyszkiewicz-Korpanty et al. [19] even sug-
gests that whole blood aggregation appears to be
more sensitive in detecting clopidogrel effects com-
pared with the platelet-rich plasma methods. The
principle of impedance aggregometry is based on
the fact that platelets get sticky upon activation, and
therefore have a tendency to adhere and aggregate
on metal sensor wires in the test cell. One Multi-
plate® test cell incorporates 2 independent sensor
units, each consisting of 2 silver-coated, highly con-
ductive wires. When activated platelets adhere to
the sensor wires the electrical resistance between
the wires rises, which is continuously registered.
The instrument detects the impedance change of
each sensor separately and transforms it to arbitrary
aggregation units (AU) that are plotted against time.
The area under the aggregation curve (AUC) is the
estimator of platelet aggregation that was evaluated
in our study. It is affected by the total height of the
aggregation curve as well as by its slope and is best
suited to express the overall platelet activity. The
aggregation quantified as the area under the curve
is displayed in arbitrary units (10 AU × min = 1 U).
In previous studies AUC has been highlighted as
the parameter with the highest diagnostic power
[16, 20]. To assess platelet response to aspirin and
clopidogrel, we applied ASPItest and ADPtest (Dy-
nabyte, Munich, Germany), respectively. The for-
mer uses arachidonic acid that serves as the sub-
strate of the cyclooxygenase for synthesis of the
potent platelet agonist, thromboxane A2, while in
the latter, adenosine diphosphate (ADP) stimulates
platelet activation by the ADP receptors that are
blocked by clopidogrel. Using this fast and standa-
rdized method, comprehensive information on
platelet function and antiplatelet therapy can be ob-
tained. Reported intra-assay coefficients of varia-
tion (CV) were 11.5% for ASPItest and 14.1% for
ADPtest, while intra-individual CVs were 11.4% for
ASPItest and 13.7% for ADPtest, respectively [18].
The producer recommends 30 U and 50 U as the
cut-off values associated with platelet hyperaggre-
gability in patients on aspirin and clopidogrel the-
rapy, respectively.
Statistical analysis
The use of the Shapiro-Wilk test demonstrated
that the investigated variables were not normally
distributed. Therefore, continuous results were repor-
ted as median values and interquartile ranges. Multi-
ple comparisons were analysed with the ANOVA
Friedman test, whereas the Wilcoxon matched-
-paired rank sum test was used for comparisons be-
tween 2 sampling points. Correlations were tested
with the Spearman rank correlation test. A value of
p < 0.05 was considered statistically significant;
0.05 ≥ p < 0.1 was regarded as a trend towards sta-
tistical significance, while p ≥ 0.1 was marked as
ns. All computations were carried out with Stati-
stica, version 8.0 (StatSoft, Tulsa, USA).
Results
A substantial circadian variation in ADP-depen-
dent platelet aggregation in subjects with STEMI
treated in line with contemporary clinical practise
was observed. Median peak values at 10.00 a.m.
were 75% higher than those measured in the early
morning (p < 0.04). A subsequent drop in platelet
aggregation in response to ADP as an agonist was
noted at 2.00 p.m. (Fig. 1). Levels of platelet aggre-
gation assessed at 6.00 a.m., 2.00 p.m. and 7.00 p.m.
in the ADP test were comparable. The ANOVA
Friedman test indicated a borderline heterogene-
ity among circadian levels of ADP-dependent pla-
telet aggregation (p = 0.073). In contrast, we did
not find any statistically significant diurnal variation
in arachidonic acid-dependent platelet aggregation,
despite a visual tendency towards increased mor-
ning aggregability (Fig. 2). However, the magnitu-
de of augmentation in this case was considerably
lower than that seen for ADP-dependent platelet
aggregation (44% vs. 75%). Baseline results of both
534
Cardiology Journal 2008, Vol. 15, No. 6
www.cardiologyjournal.org
ADP and ASPI tests did not correlate with their
highest levels. Aggregation measurements at each
time point were unrelated to the platelet count as
well as mean platelet volume. The vast majority of
the ADP test results and all ASPI test results in our
patients were below the cut-off values that, accor-
ding to the producer, may be associated with aspi-
rin and clopidogrel resistance, respectively.
Discussion
Numerous trials have reported on the morning
increase in the occurrence of myocardial infarction,
stroke and sudden cardiac death. This well-known
phenomenon seems to be attributed to numerous
pathomechanisms such as the morning surge in pla-
telet aggregability accompanied by a trough in the
fibrinolysis system, an increased morning throm-
bin formation coexisting with a morning peak in
blood pressure triggered by sympathetic overacti-
vity and cortisol hypersecretion [21]. In particular,
the extensive morning release of catecholamines
promotes thrombus formation and enhances my-
ocardial vulnerability. Previous studies indicate that
assuming an upright posture and initiation of daily
activities occupy a crucial role in morning platelet
hyperaggregability in healthy subjects [9, 22].
A particularly pronounced platelet hyperresponsi-
veness to physical exercise appears in habitually in-
active subjects [23].  Andrews et al. [24], in a so-
phisticated flow cytometric study, proved that the
morning increase in platelet aggregation does not
occur with expression of activation-dependent pla-
telet surface receptors. In another experimental
work these researchers successfully attenuated the
morning orthostatic increase in platelet aggregation
by an alpha2-adrenergic blockade with yohimbine [25].
Similarly, guanabenz, a centrally acting alpha2-ago-
nist exerting antihypertensive properties, suppres-
sed morning elevations in aggregation of human
platelets [26]. However, Willich et al. [27] showed
in a well-designed study that alpha2-adrenergic re-
ceptor density and agonist binding affinity assessed
simultaneously did not change after arising. They
also suggested that the increase in platelet aggre-
gability is due to factors extrinsic to the platelets
or to an intra-platelet mechanism distal to the re-
ceptor level.
According to our knowledge, we demonstrated
for the first time that increased morning ADP-de-
pendent platelet aggregation persists despite dual
antiplatelet therapy in patients with first ST-seg-
ment elevation myocardial infarction. On the other
hand, we failed to show any statistically significant
circadian variation in platelet aggregation in respon-
se to arachidonic acid in this group, despite a visual
tendency towards differentiated diurnal platelet
response to aspirin, as illustrated in Figure 1. Mo-
reover, the magnitude of the morning surge in pla-
telet aggregation after ADP stimulation was not
associated with its baseline level.
Several facts should be taken into account
when interpreting our findings. A large body of evi-
dence has emerged which highlights the limited
potential of aspirin in terms of antiplatelet proper-
ties. Larsson et al. [28] indicated that norepineph-
rine-induced platelet activation in vivo is only par-
tly counteracted by aspirin in normal subjects.
Figure 1. Circadian variation in adenosine diphosphate
-dependent platelet aggregation assessed on the 3rd day of
hospitalization in patients with ST-segment elevation myo-
cardial infarction treated with dual antiplatelet therapy.
Figure 2. Circadian variation in arachidonic acid-depen-
dent platelet aggregation assessed on the 3rd day of hos-
pitalization in patients with ST-segment elevation myo-
cardial infarction treated with dual antiplatelet therapy.
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Similarly, Rinder et al. [29] failed to inhibit by aspi-
rin the adenosine diphosphate-induced platelet
alpha-granule release. Furthermore, in another expe-
riment fibrinogen binding to unstimulated platelets
or to platelets stimulated with ADP or thrombin was
unaffected by aspirin in healthy subjects [30]. Addi-
tionally, aspirin treatment in the normal population
did not attenuate platelet or leukocyte activation as
monitored by whole blood flow cytometry [31].
Finally, in a Swedish study aspirin only modestly
suppressed the prothrombotic effects triggered by
vigorous exercise [32]. Contrary to these data, ente-
ric-coated aspirin markedly reduced baseline platelet
thromboxane A2 production in healthy males and
eliminated its increase after the subjects got up [33].
It also abolished biphasic aggregation in response to
epinephrine and ADP. The lack of morning increase
in thromboxane A2 synthesis observed by McCall et
al. [33] corresponds with our results, indicating sup-
pression of the circadian variation in thromboxane
A2-dependent platelet aggregation. On the other
hand, the enhanced morning response to ADP that
persisted in our trial despite the addition of clopido-
grel contrasts with the findings of American resear-
chers. However, it must be stressed that both stu-
dies examined different populations: healthy subjects
vs survivors of myocardial infarction reflecting the
opposite ends of the thrombotic milieu.
The limitations of clopidogrel therapy are cur-
rently widely discussed. The major drawbacks of
clopidogrel include delayed onset of action, modest
antiplatelet effect and substantial interpatient va-
riability. Perneby et al. [34] reported that clopido-
grel treatment in healthy volunteers attenuated
platelet activity in vivo at rest, but exercise coun-
teracted the platelet stabilizing effects of clopido-
grel. The authors also extended their observations
to patients with stable coronary artery disease. In
this group, dual antiplatelet treatment did not re-
duce ECG signs of either exercise-induced or am-
bulatory myocardial ischemia [35]. Moreover,
Eikelboom et al. [36] suggest that the clinical be-
nefits of clopidogrel are not associated with a paral-
lel reduction in markers of coagulation activation
such as P-selectin, prothrombin fragment F1.2,
D-dimer or von Willebrand factor.
Due to the limited number of patients in our
trial, we plan to validate our results in a larger co-
hort. If our findings confirm, further  studies to cla-
rify their clinical significance are warranted. We are
of the opinion that the periodicity in platelet aggre-
gation present on antiplatelet therapy should be ad-
justed for the discriminative ability of various me-
thods applied in the analysis of platelet function.
Pepine [21] suggests that attention to the vulnera-
ble morning period is merited in the timing and
choice of medication, both to prevent or reduce
ischemia and to modify potential disease-triggering
mechanisms. We speculate that suppression of the
morning increase in platelet aggregability by novel
potent antiplatelet agents may further improve the
long-term prognosis in survivors of myocardial infarc-
tion. The results of the Physicians’ Health Study as-
signing 22 071 US male physicians to aspirin (325 mg
daily) or placebo support this hypothesis [37]. Ridker
et al. [37] reported that aspirin use when compared
to placebo was associated with a 59.3% reduction in
the incidence of infarction during the morning wa-
king hours, compared with a 34.1% reduction for
the remaining hours of the day. Nevertheless, we
feel obligated to emphasize that, despite a tempo-
ral association between increased platelet aggrega-
bility in the morning and an increased frequency of
myocardial infarction and stroke and sudden cardiac
death, a cause-effect relation has been suggested
but never proven [9]. In our study we applied im-
pedance aggregometry. As a consequence of the fact
that the Multiplate® is a newly invented device, the
data assessing its diagnostic power are still sparse.
Nevertheless, in a study by Mengistu et al. [38] im-
pedance aggregometry with the Multiplate® devi-
ce, but not thromboelastography, successfully pre-
dicted the postoperative requirements for blood
transfusion in patients undergoing cardiac surgery.
Similarly, a recent trial including 50 consecutive pa-
tients scheduled for neuro-interventional stent pla-
cement procedures demonstrated an unfavourable
clinical outcome in clopidogrel nonresponders [39].
To conclude, increased morning ADP-depen-
dent platelet aggregation persists despite dual an-
tiplatelet therapy in patients with first ST-elevation
myocardial infarction. The clinical significance of
this finding remains to be demonstrated.
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